阿利吉仑单用及联用阿托伐他汀对动脉粥样硬化小鼠炎症因子的影响

发布时间：2018-02-21 16:19

本文关键词： 阿利吉仑阿托伐他汀 apoE-/-雄性小鼠动脉粥样硬化炎症因子　出处：《中国医院药学杂志》2015年12期 　论文类型：期刊论文

【摘要】：目的:考察阿利吉仑单用或与阿托伐他汀联用对动脉粥样硬化小鼠炎症因子的影响。方法:将12周龄apoE-/-雄性小鼠给予高脂饮食,随机分为6组(n=8),包括模型对照组,肼屈嗪组、阿利吉仑低剂量组、阿利吉仑高剂量组、阿托伐他汀组、阿利吉仑与阿托伐他汀联合用药组,均治疗12周。采用酶联免疫吸附的方法(ELISA)测定血浆中白介素-6(IL-6)、C反应蛋白(CRP)和单核细胞趋化蛋白-1(MCP-1)的水平;光学显微镜下测定动脉粥样硬化病变区与总主动脉面积。结果:与模型对照组相比,阿利吉仑单独用药对炎症因子MCP-1的影响无显著性差异。阿利吉仑单独或者联合阿托伐他汀用药能够显著降低炎症介质IL-6、CRP的血浆水平(P0.05),且阿利吉仑高、低剂量组之间对CRP和IL-6水平的影响亦有差异;阿利吉仑联用阿托伐他汀与阿托伐他汀组对MCP-1、IL-6、CRP水平的影响均无显著性差异(P0.05)。组织病理学结果显示:单用阿利吉仑或联合应用阿托伐他汀都有不同程度的降低动脉粥样硬化面积,与模型对照组相比均有显著性差异,且单用阿利吉仑组、阿托伐他汀组均与联合用药组有显著性差异(P0.05)。结论:阿利吉仑对动脉粥样硬化小鼠体内炎症因子水平有一定影响,并显示出一定的剂量依赖性,同时与阿托伐他汀合用有一定的联合治疗作用。
[Abstract]:Objective: to investigate the effect of alligilun alone or combined with Atto vastatin on inflammatory factors in atherosclerotic mice. Methods: 12-week-old apoE-r-male mice were randomly divided into 6 groups, including model control group and hydrazine group. Alligilun low dose group, alligilun high dose group, Atto vastatin group, alligilun combined with Atto vastatin group, All patients were treated for 12 weeks. Plasma levels of interleukin-6, IL-6, C-reactive protein (CRP) and monocyte chemoattractant protein (MCP-1) were determined by Elisa. The area of atherosclerotic lesion and total aorta were measured under optical microscope. Results: compared with the model control group, There was no significant difference in the effect of alligilun alone on the inflammatory factor MCP-1. Alligilun alone or in combination with Atto vastatin could significantly reduce the plasma level of IL-6 MCP-1, and the level of alligilun was higher than that of alligilun. The effects of low dose groups on the levels of CRP and IL-6 were also different. There was no significant difference in the effect of alligilun combined with Atto vastatin and Atto vastatin on the level of MCP-1and IL-6 CRP. The histopathological results showed that either alligilun alone or Atto vastatin could decrease the area of atherosclerosis in varying degrees. Compared with the model control group, there were significant differences between the alligilun group and the Atto vastatin group. Conclusion: alligilun has a certain effect on the level of inflammatory cytokines in atherosclerotic mice. It also showed certain dose dependence and combined therapy with Atto vastatin.
【作者单位】：华中科技大学同济医学院附属协和医院药学部;
【分类号】：R965

【共引文献】